BioprintingMedical Research

nScrypt’s Sciperio and partners developing biomanufactured human blood

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Sciperio, the research arm of Florida-based nScrypt, has announced a joint project with several partners through which it will seek to develop on-demand human blood for future blood supply. The project will leverage nScypt’s microdispensing technology and will be undertaken in collaboration with The Uniformed Services University of the Health Sciences’ (USU) 4D Bio3 program, The Geneva Foundation, Safi Biosolutions, Advanced Bioprocess Services, and Massachusetts General Hospital.

The first year of the collaborative research project, for which Sciperio and Safe Biosolutions have been awarded $8.8 million in funding, will be focused on establishing a “Whole blood development roadmap.” In this initial phase, Sciperio will also develop a highly automated rugged bioreactor with multiple sensors for real-time feedback and control, which will be constructed by nScrypt.

Sciperio nScrypt blood

Dr. Ken Church, CEO of nScrypt and Sciperio, elaborated on the project, saying: “How do you manufacture blood at a scale relevant for patient use? We are using several nScrypt SmartPump tool heads to precisely microdispense growth enhancers in the bioreactor, causing cell expansion and differentiation. The bioreactor makes it scalable. There are so many interesting aspects and advantages of biomanufacturing blood, including the ultimate benefit to humanity. Starting with a few cells, our bioreactor will produce billions of cells, a necessary requirement for patient transfusion. We believe this exciting project will one day result in a steady source of safe and affordable on-demand blood made where and when it’s needed.”

The goal of the project is to develop a biomanufacturing solution which could produce viable human blood on demand for transfusions. The ability to produce human red blood cells on-site could alleviate strains on blood donation supplies, especially on the battlefield and in remote locations. Traditional blood supply networks, which rely on donors, come with their challenges, including blood screening concerns, complex logistics and short-term storage. Biofabricated blood could offer a potential solution when these blood donor networks face limitations.

nScrypt, a company which designs and manufactures high-precision microdispensing and 3D printing equipment, has also developed a bioprinter which has been ruggedized for use in military contexts.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.